Overexpression of her2. Medical search. Frequent questions

HER2 overexpression and/or amplification is an oncogenic driver in multiple tumor types, as well as a potential therapeutic target. (her2centrality.com)
Systematic literature review of HER2 amplification/overexpression in colorectal cancer. (her2centrality.com)
Amplification of the human epidermal growth factor receptor 2 ( HER2 ) gene and overexpression of the HER2 protein is found in 15%-20% of patients with gastric and gastroesophageal junction cancer. (wjgnet.com)
The degree of HER2 overexpression and amplification varies with the location of the carcinoma, with higher expression in the gastroesophageal and proximal parts compared to the distal parts of the stomach. (wjgnet.com)
Further, HER2 overexpression and amplification also seems to be related to the Lauren histological classification, with higher levels found in the intestinal phenotype compared to the diffuse and mixed types. (wjgnet.com)
The prognostic properties of HER2 overexpression and amplification are still under debate, but a large number of studies seem to indicate that HER2 is a negative prognostic factor. (wjgnet.com)
Central confirmation of HER2 amplification was required by fluorescence in-situ hybridisation (FISH), and testing was only allowed on tumor tissue. (medpagetoday.com)
Another risk factor, however, is HER2 gene amplification/overexpression. (curetoday.com)
HER-2/neu amplification predicts poor survival in node-positive breast cancer. (thieme-connect.de)
Scrotal Paget's disease associated with metastatic carcinoma with apocrine features and ERBB2-amplification/HER2 overexpression responding well to weekly paclitaxel combined with trastuzumab and pertuzumab. (aau.dk)
Alterations in receptor tyrosine kinases (TKs), such as the epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor 1, include overexpression, amplification or mutations. (bmj.com)
HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay (see sections 4.4 and 5.1). (who.int)
Amplification of the ErbB-2 gene and overexpression of its product has been detected in almost 40% of primary human breast tumors, which correlates with poor prognosis in node positive breast cancer. (activemotif.com)
Human epidermal growth factor receptor 2 (Her2) refers to an oncogene whose over-expression or amplification is commonly associated with the development of an aggressive type of breast cancer. (openpr.com)
HER2 overexpression may be associated with a specific HER2 gene alteration known as HER2 amplification and is often associated with aggressive disease and poor prognosis in breast cancer. (biospace.com)
Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication. (cdc.gov)
The results of ABCC3 were correlated with the amplification status of HER2 and topoisomerase II alpha (TOP2A), which are located close to ABCC3 at 17q12-q21. (lu.se)
Of the cell lines studied 6 HER2-positive lines and 1 HER2-negative line exhibited amplification of ABCC3. (lu.se)
ABCC3 (MRP3) protein overexpression was more common in tumors with gene amplification (P = 0.069). (lu.se)

These "HER2-positive" tumors are associated with more rapid progression, decreased survival, and increased tumor recurrence. (snpedia.com)
People who have never smoked, are female, and are of Asian descent are more likely to have a HER2 mutation in their lung tumors, he noted. (cancer.gov)
That's slightly different from breast cancer, in which tumors can have high levels of the HER2 protein from gene overexpression , he said. (cancer.gov)
SAN ANTONIO - Should breast cancer patients with low but not negative tumor expression of HER2 be considered a distinct patient group that can be treated differently from patients with tumors that are HER2 negative or HER2 positive? (medscape.com)
However, a recent pooled analysis of more than 3500 patients across four trials, published in The Lancet Oncology in 2021, revealed that patients with HER2 low tumors had fewer grade 3 tumors, lower tumor proliferation, and improved disease-free survival (DFS), in particular, patients with hormone receptor negative (HR) disease. (medscape.com)
HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of many types of tumors including breast, gastric, lung and colorectal cancers. (biospace.com)
Triple-negative tumors (ER - /PR - /HER2 - ) have been reported to be more common among younger women, but occurrence of the spectrum of breast cancer subtypes in adolescent and young adult (AYA) women aged between 15 and 39 years is otherwise poorly understood. (cdc.gov)
When breast cancer occurs in AYAs, it differs from that occurring in older women in several ways: a worse prognosis and more-aggressive phenotype, higher proportions of high-grade and later stage tumors, lower estrogen receptor (ER) positivity, and overexpression of human epidermal growth factor receptor 2 (HER2) [ 1 , 3 , 4 ]. (cdc.gov)
We recently reported in a large, population-based series from California that the hormone receptor negative, HER2 positive (HR - /HER2 + ) and triple-negative (ER negative/progesterone receptor (PR) negative/HER2 negative) tumors were more common in younger women [ 4 , 6 ]. (cdc.gov)
In the HER2-positive tumors, ABCC3 was amplified in 16/57 tumors (28.1%, P = 0.0059). (lu.se)
Specifically, increased ABCC3 mRNA and gene copy numbers were most prominent in HER2 amplified and/or HER2-enriched classified tumors. (lu.se)
Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors. (cdc.gov)

It reduces production of a protein from the HER2 gene, which is overexpressed ~25% of breast cancers. (snpedia.com)
CHICAGO -- In a pair of mid-stage trials, newer targeted therapies demonstrated meaningful levels of activity against HER2-positive biliary tract cancers in pretreated patients with advanced disease. (medpagetoday.com)
Furthermore, he said, not all types of biliary cancers express HER2 the same way. (medpagetoday.com)
From September 2020 to March 2022, the HERIZON-BTC-01 trial enrolled 87 patients with locally advanced or metastatic HER2 -amplified biliary cancers across 32 sites in Asia, Europe, North America, and South America. (medpagetoday.com)
In mouse and rat xenograft tumor models, TAK-285 showed antitumor activity against cancers that expressed HER2 or EGFR. (jcancer.org)
HER2/neu (cerbB2) (human epidermal growth factor receptor 2) is an oncogene which is over-expressed in approximately 20% of breast cancers. (bccancer.bc.ca)
P53 overexpression is less frequent in hormone receptor positive breast cancers. (cancerindex.org)
Download these slides on assessment of HER2 overexpression in GI cancers. (clinicaloptions.com)
Some types of cancer cells make larger than normal amounts of HER2, including certain cancers of the breast , stomach , and esophagus . (medlineplus.gov)
Cancers with large amounts of HER2 protein tend to grow quickly and spread to other parts of the body. (medlineplus.gov)
Certain medicines, called HER2 targeted therapy, can block or slow HER2 proteins and help control these cancers. (medlineplus.gov)
But these medicines won't help cancers that don't have high levels of HER2 proteins. (medlineplus.gov)
But certain cancers have extra copies of the HER2 gene, which leads to too much HER2 protein on the cancer cells. (medlineplus.gov)
These cancers are likely to respond to HER2 targeted therapy. (medlineplus.gov)
HER2 tumor marker tests are mostly used to find out whether certain cancers are HER2 positive or negative. (medlineplus.gov)
Cancer of the pancreas, bladder, ovaries , or certain other cancers that may have high levels of HER2 which may be treated with medicines that target HER2. (medlineplus.gov)
Several studies have shown that HER-2/neu, also known as c-erbB-2, is amplified and overexpressed in many cancers. (go.jp)
Breast cancers are increasingly recognized as heterogeneous based on expression of receptors for estrogen (ER), progesterone (PR), and human epidermal growth factor receptor 2 (HER2). (cdc.gov)
Data regarding all 5,605 AYA breast cancers diagnosed in California during the period 2005 to 2009, including ER and PR status (referred to jointly as hormone receptor (HR) status) and HER2 status, was obtained from the population-based California Cancer Registry. (cdc.gov)
Therefore, the better to understand the occurrence of AYA breast cancer subtypes, we took advantage of HER2 data recently available for breast cancers occurring in the large and diverse California population from 2005 to 2009. (cdc.gov)

HER2 positive , which means the cancer has high levels of the HER2 protein or HER2 genes. (medlineplus.gov)

Martínez-Sáez O, Prat A. Current and future management of HER2-positive metastatic breast cancer. (her2centrality.com)
Over the past several years, multiple treatment advancements have given oncologists the ability to better target brain metastases in patients with HER2-positive metastatic breast cancer. (curetoday.com)
Substantial advancements over the past several years have given rise to a more tailored approach in the treatment of active central nervous system disease - particularly brain metastases - in patients with HER2-postive metastatic breast cancer, according to an expert. (curetoday.com)
Within the HER2 subtype, the SystHERs study of 977 patients further identified an age of less than 50 years, recurrent metastatic breast cancer and hormone-receptor negative status as additional risk factors for central nervous system metastases. (curetoday.com)
Brain metastases often occur quickly during the course of HER2-positive metastatic breast cancer, and (that) negatively impacts quality of life and overall survival," Pegram said. (curetoday.com)
In these studies, a high-dose version of Herceptin (trastuzumab) was tested in combination with Perjeta (pertuzumab) for patients with HER2-positive metastatic breast cancer with progressive brain metastases, with promising results demonstrated in the phase 2 PATRICIA study (NCT02536339). (curetoday.com)
Herceptin) in patients with HER-2/neu overexpressing unresectable or metastatic non-small cell lung cancer (closed to accrual as of 4/16/01) or refractory locally advanced or metastatic breast cancer. (knowcancer.com)
Many patients with HER2 positive metastatic breast cancer have aggressive disease due to progression from an earlier stage, with a significant proportion having their disease relapse after receiving THP or other standard anti-HER2 therapies in an adjuvant setting. (biospace.com)
1 Research has also shown that patients often progress in less than two years following initial treatment for HER2 positive metastatic breast cancer. (biospace.com)
Based on the encouraging results we are seeing in patients who have received prior treatment for HER2 positive metastatic breast cancer, we have initiated DESTINY-Breast09 to evaluate whether earlier use of ENHERTU alone or as part of a novel combination regimen may help improve outcomes for patients in the first-line metastatic setting as compared to the current standard of care. (biospace.com)
DESTINY-Breast09 is a global head-to-head phase 3 trial evaluating the safety and efficacy of ENHERTU (5.4 mg/kg) with or without pertuzumab compared to standard of care (THP: taxane [docetaxel or paclitaxel], trastuzumab and pertuzumab) as a first-line treatment in patients with HER2 positive metastatic breast cancer. (biospace.com)
In the first-line HER2 positive metastatic breast cancer setting, approximately 50% of cases are considered de novo , meaning the disease is metastatic from initial diagnosis, while the remaining cases occur due to disease progression from early stage disease. (biospace.com)

c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. (thieme-connect.de)
Immunohistochemistry was used to assess ABCC3 protein overexpression. (lu.se)

We then outline preclinical approaches that employ CAR-NK cells for GB immunotherapy, and give an overview on the ongoing clinical development of ErbB2 (HER2)-specific CAR-NK cells currently applied in a phase I clinical trial in glioblastoma patients. (frontiersin.org)
Confocal immunofluorescent analysis of MDA-MB-453 cells (left) and MDA-MB-231 cells (right), using HER2/ErbB2 (29D8) Rabbit mAb (green). (cellsignal.com)
Flow cytometric analysis of MDA-MB-468 cells (blue) and SKBR3 cells (green) using HER2/ErbB2 (29D8) Rabbit mAb (solid lines) or a concentration-matched Rabbit (DA1E) mAb IgG XP ® Isotype Control #3900 (dashed lines). (cellsignal.com)
Western blot analysis of cell extracts from various cell lines, using HER2/ErbB2 (29D8) Rabbit mAb. (cellsignal.com)
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using HER2/ErbB2 (29D8) Rabbit mAb. (cellsignal.com)
Immunohistochemical analysis of paraffin-embedded human breast carcinoma using HER2/ErbB2 (29D8) RmAb in the presence of control peptide (left) or HER2/ErbB2 Blocking Peptide #1059 (right). (cellsignal.com)
Immunohistochemical analysis of paraffin-embedded SKBr3 (high HER2) (left), MDA-MB-453 (moderate HER2) (middle) and MDA-MB-468 (low HER2) (right), using HER2/ErbB2 (29D8) Rabbit mAb. (cellsignal.com)

Patients who had overexpression of the HER 2 genes responded to herceptin, whereas those without HER2 overexpression did not [1] . (snpedia.com)
HER2 overexpression is associated with a poor prognosis, possibly differences in response to different cytotoxics and is a predictor for responsiveness to Herceptin® (trastuzumab). (bccancer.bc.ca)
For 2+ tests, FISH testing is of value to identify true HER2 positive over-expression which may benefit from Herceptin® therapy and may be of greater predictive value than the IHC testing. (bccancer.bc.ca)
3 Baselga J, Norton L, Albanell J, Kim Y M, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. (thieme-connect.de)
The key Her2 antibodies available in the global market for the treatment of breast cancer include lapatinib (Tykerb), tratuzumab (Herceptin), Pertuzumab (Perjeta), Everolimus (Afinitor), and Ado-trastuzumab emtansine (TDM-1, Kadcyla). (openpr.com)
Of these, tratuzumab (Herceptin) is presently the most widely prescribed Her2 antibody drug for breast cancer. (openpr.com)

This assay assists in determining eligibility for HER2 therapy in patients with CRC. (labcorp.com)
The usefulness of HER2 targeted therapy in gastric cancer was demonstrated in the ToGA trial, where HER2-positive patients with advanced gastric and gastroesophageal junction adenocarcinoma were randomized to receive 5-FU/capecitabine and cisplatin, either alone or in combination with trastuzumab. (wjgnet.com)
Patients with a strong overexpression of the HER2 protein (IHC3+) specifically benefited from the treatment, with a median overall survival of 17.9 mo. (wjgnet.com)
As a consequence of the positive results of the ToGA trial, patients with advanced gastric or gastroesophageal junction adenocarcinoma are now routinely tested for HER2. (wjgnet.com)
Cohort 1 of the global HERIZON-BTC-01 study, which included 80 treatment-refractory patients, showed that 41.3% (95% CI 30.4-52.8) responded to zanidatamab, an investigational bispecific monoclonal antibody that targets two distinct HER2 epitopes, according to Shubham Pant, MD, of the MD Anderson Cancer Center in Houston. (medpagetoday.com)
And in a smaller study, the dual HER2-targeted strategy of tucatinib (Tukysa) plus trastuzumab induced responses in 46.7% (90% CI 30.8-63.0) of the 30 patients with metastatic disease, reported Yoshiaki Nakamura, MD, PhD, of the National Cancer Center Hospital Japan East in Kashiwa. (medpagetoday.com)
Furthermore, multiple HER2 testing modalities were shown to be reliable in identifying patients who may be eligible for this treatment regimen. (medpagetoday.com)
Cohort 1 included 80 patients with HER2 expression defined as an immunohistochemistry (IHC) score of 2+ or 3+, with about three-fourths having IHC 3+. (medpagetoday.com)
Tukysa)-based therapy improves overall survival for patients with HER2-positive breast cancer with brain metastases, while maintaining overall health-related quality of life, with some potential benefit also seen in leptomeningeal metastasis. (curetoday.com)
En conséquence, 47 % de ces patients présentaient un stade avancé (III et IV). (who.int)
In cancer tissues, expression of IL-33 was higher than matched normal breast tissues from the same patients, and was also associated with a well-differentiated phenotype, HER2 overexpression, more lymph nodes involvement, and a family history of malignant carcinoma. (frontiersin.org)
The HER-2/neu onkogene may play a role in the prognosis and management of patients with breast cancer. (thieme-connect.de)
32 % of patients exhibited overexpression of HER-2/neu. (thieme-connect.de)
Expression analyses of epidermal growth factor receptor and HER-2/neu: no advantage of prediction of recurrence or survival in breast cancer patients. (thieme-connect.de)
But all patients with advanced NSCLC should get biomarker testing for this HER2 mutation and other mutations that have matching targeted therapies , Dr. Li said, such as those in the EGFR , ALK , and BRAF genes. (cancer.gov)
Patients having the over-expression of Her2 receptors are diagnosed with the help of tests such as Fluorescent In-Situ Hybridization (FISH) and Immunohistochemistry (IHC). (openpr.com)
The high disposable incomes and favorable reimbursement policies make Her2 antibody treatment affordable for patients in the region, which is also a key factor to have driven the market for Her2 antibodies over the past few years. (openpr.com)
He admitted that, while there have been many studies, the majority have found no overall survival difference between breast cancer patients whose disease could be classified as HER2 low as opposed to HER2 negative or zero. (medscape.com)
Another study presented at SABCS 2022, which involved patients with early-stage invasive lobular carcinoma of the breast, suggested that HER2 low status was associated with worse DFS when compared to HER2-negative status, as well as progesterone receptor positivity. (medscape.com)
This is the first trial to evaluate ENHERTU in the first-line metastatic setting in patients with HER2 positive breast cancer. (biospace.com)
1 While there have been substantial advances in the treatment of these patients, there remains an ongoing need to improve outcomes, and as a result more effective HER2 directed treatments and novel combination regimens are needed. (biospace.com)
AYAs had higher proportions of HR + /HER2 + , triple-negative and HR - /HER2 + breast cancer subtypes and higher proportions of patients of non-White race/ethnicity than did older women. (cdc.gov)

Specificity validation of anti-Her2 antibody (Cat. (origene.com)

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. (her2centrality.com)
The ToGA trial must be characterized as a landmark in the treatment of gastric cancer and it has paved the way for a number of new HER2 targeted compounds such as pertuzumab, ado-trastuzumab emtansine, lapatinib, afatinib, and dacomitinib, which are currently undergoing phase II and III clinical testing. (wjgnet.com)
Trastuzumab blocks overexpression of HER2. (snpedia.com)
Breast cancer therapy has improved following the development of drugs with specific molecular targets, exemplified by inhibitors of human epidermal growth factor receptor-2 (HER2) or epidermal growth factor receptor (EGFR) such as trastuzumab and lapatinib. (jcancer.org)
On August 11, the Food and Drug Administration (FDA) gave accelerated approval to trastuzumab deruxtecan (Enhertu) for adults with NSCLC that has a certain kind of mutation in the HER2 gene (called an "activating" mutation). (cancer.gov)
Herzuma (trastuzumab-pkrb) is a HER2 /neu receptor antagonist indicated for the treatment of HER2-overexpressing breast cancer . (rxlist.com)
HERZUMA (trastuzumab-pkrb) is a humanized IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2 . (rxlist.com)
Treatment with trastuzumab is well established in breast cancer with HER-2 overexpression and is recommended by several consensus statements. (go.jp)
The company plans to launch new drugs in the Her2 antibody category - Pertuzumab (Perjeta) and Ado-trastuzumab emtansine (TDM-1, Kadcyla). (openpr.com)

Romero endured another round of chemotherapy, this time in pill form, as well as targeted therapy against HER2, but the spots remained on his liver. (ucdavis.edu)
The market for Her2 antibodies in regions such as Asia Pacific will be driven chiefly due to regulatory support and the increased adoption of chemotherapy for the treatment of breast cancer. (openpr.com)

The specificity is further proved by using an independent antibody (anti-DDK antibody in the middle) against the same recombinant overexpressed Her2 protein. (origene.com)
The field of Her2 antibodies has witnessed a significant rise in attention over the past few years owing to the effectiveness of Her2 antibody-based drugs and rising prevalence of breast cancer. (openpr.com)
These authors concluded that it is "unclear whether these slight differences in outcomes justify classification of HER2 low disease as a unique subtype," although the use of novel antibody-drug conjugates could "drastically change" outcomes, Curigliano commented. (medscape.com)

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. (her2centrality.com)
HER2 is a known negative predictive biomarker in colorectal cancer (CRC). (labcorp.com)
HER2 testing in colorectal cancer: concordance analysis between breast and gastric scoring algorithms from the MOUNTAINEER trial. (labcorp.com)
Djaballah SA, Daniel F, Milani A, Ricagno G, Lonardi S. HER2 in colorectal cancer: the long and winding road From negative predictive factor to positive actionable target. (labcorp.com)

Diversification of neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. (her2centrality.com)
HER2/neu (also called ERB B2 ) is the gene that encodes the human epidermal growth factor receptor type 2. (cancerquest.org)
Current therapies target the overexpression of progesterone (PR), estrogen (ER) or human epidermal growth factor 2 (HER2). (aiche.org)
OBJECTIVES: Human epidermal growth factor receptor-2 (HER2) and 3 (HER3) belong to the epidermal growth factor receptor (EGFR) family of transmembrane receptor tyrosine kinases. (koreamed.org)
Based on new findings, UC Cancer Institute scientists believe that tamoxifen resistance may be driven by a novel molecular 'crosstalk point between the estrogen and HER2 (human epidermal growth factor receptor 2) signaling pathways. (uc.edu)
this may be in part because they have a higher rate of triple-negative breast cancer (negative for estrogen and progesterone receptors and human epidermal growth factor receptor [HER2] oncogene), which has a poorer prognosis than other types. (msdmanuals.com)
The Immuno-histo-chemical analysis useip (estrogen receptors) RE, the PR (progesterone receptors), the ((Human Epidermal Growth Factor Receptor-2), the Ki67 (proliferation marker) HER2, CK5/6) has shown a subdivision into subgroups similar to those found by genomic analysis. (bvsalud.org)
The status of the erbB-2 (human epidermal growth factor receptor 2/neu) proto-oncogene in canine osteosarcoma (OSA) has not been reported previously. (cdc.gov)

Overall, this review will discuss the current status of HER2 in gastric and gastroesophageal junction cancer and the future direction in relation to HER2 target therapy. (wjgnet.com)
ErbB-2 overexpression is also observed in ovarian, gastric, salivary and non-small cell lung carcinomas. (activemotif.com)

HR - /HER2 + ), and logistic regression was used to evaluate differences in subtype characteristics by age group. (cdc.gov)

In TGF-beta-treated MCF10A mammary epithelial cells overexpressing HER2 and by chromatin immunoprecipitation, we identified novel Smad targets including protein tyrosine phosphatase receptor type kappa (PTPRK). (nih.gov)
Endogenous RPTPkappa associated with EGF receptor and HER2, resulting in suppression of basal and ErbB ligand-induced proliferation and receptor phosphorylation. (nih.gov)
Association of p53 Overexpression with Hormone Receptor Status and Triple Negative Breast Carcinoma. (cancerindex.org)
To determine association of p53 overexpression with hormone receptor status in breast carcinoma. (cancerindex.org)
Further mechanistic studies showed that HER2 activation of MED1 resulted in the recruitment of co-activators instead of co-repressors by tamoxifen-bound estrogen receptor. (uc.edu)
This, explains Zhang, drives expression of not only traditional estrogen receptor-positive cancer target genes, but also HER2 and those estrogen receptor target genes abnormally activated by HER2. (uc.edu)
The ErbB-2 proto-oncogene, also called Neu, EGFR-2 or HER-2, is a member of the transmembrane receptor tyrosine kinase family, which also includes EGF receptor and EGFR-3 (HER-3 or ErbB-3). (activemotif.com)
Her2 antibodies are reported to mediate the regression of tumor by interrupting oncogenic signals and/or inducing Fc receptor-mediated cytotoxicity. (openpr.com)

Prospective studies correlating HER-2/neu overexpression with prognosis might provide additional data. (thieme-connect.de)

We are currently utilizing RNA-based nanotechnology to target MED1 in an effort to simultaneously block both estrogen and HER2 pathways to overcome endocrine-resistant breast cancer. (uc.edu)

Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. (her2centrality.com)
So, HER2 tumor marker testing is necessary to find out if targeted therapy will be helpful. (medlineplus.gov)
HER2 targeted therapy will not work for this type of cancer, but other treatment options may help. (medlineplus.gov)
HER2 testing is mandatory prior to initiation of therapy (see sections 4.4 and 5.1). (who.int)

Ko cautioned, however, that each trial had differences in eligibility criteria and definitions for HER2-positive disease, with activating HER2 mutations (often not associated with overexpression) used for eligibility in some tyrosine kinase inhibitor trials. (medpagetoday.com)
But right now what I can say is that every patient that we have with advanced biliary cancer, whose treatment is planned, should be tested for HER2 expression and probably for HER2 mutations as well. (medpagetoday.com)
Alongside Enhertu, FDA approved two companion diagnostic tests that check for HER2 gene mutations: Guardant360 CDx, which uses a blood sample, and Oncomine Dx Target Test, which uses a sample of tumor tissue. (cancer.gov)
The HER2 mutations seen in lung cancer make the HER2 protein activated all the time, Dr. Neal explained. (cancer.gov)

con presentación clínica inicial en etapas localmente avanzadas, con diagnóstico de carcinoma de mama invasivo de tipo no especial, pobremente diferenciado y receptores para estrógeno y progesterona positivos. (bvsalud.org)

HER2 signaling is a driver of tumor cell proliferation and survival. (her2centrality.com)
The HER2/HER3 heterodimer delivers the most potent signal for proliferation in tumor cells that overexpress HER2. (her2centrality.com)

We investigated the effects of TAK-285, a novel, investigational, dual EGFR/HER2 inhibitor that has been shown to penetrate the CNS and has comparable inhibitory efficacy to lapatinib which is a known Pgp substrate. (jcancer.org)
Only negative triple cases (HR and HER2 negative) benefited from an additional marking with CK5/6 and EGFR to set the basal profile. (bvsalud.org)

Recent trials have established HER2 as a therapeutic target in CRC. (labcorp.com)
The observed overexpression of HER-2 in EMPD presents a potential therapeutic target for adjuvant treatment of this disease. (go.jp)

Up until this point, there were no FDA-approved targeted therapies for HER2 -mutant lung cancer," Dr. Neal added. (cancer.gov)
Opening the debate was Giuseppe Curigliano, MD, PhD, director of new drugs and early drug development for the Innovative Therapies Division at the European Institute of Oncology, Milan, Italy, who argued the case that HER2 low is a separate clinical entity. (medscape.com)
Given the importance of erbB-2 in human breast cancer, the finding of erbB-2 overexpression in canine OSA may be important in further understanding the pathogenesis and possible therapies of OSA. (cdc.gov)

Expression levels of miR-101-5p in two clinical datasets, TCGA and METABRIC, were compared between tumor and normal adjacent samples, and across molecular subtypes and HER2 status. (nih.gov)
After two decades of failed attempts in clinical trials, we have learned more about the biology of HER2 in lung cancer," said, Bob T. Li, M.D., Ph.D., M.P.H., of Memorial Sloan Kettering Cancer Center. (cancer.gov)
But in an earlier clinical trial of Enhertu for people with metastatic HER2 -mutant NSCLC, 37% of the 91 participants had stable disease . (cancer.gov)
Testing in both pre-clinical models and human breast cancer tissue samples showed that MED1 co-amplifies and co-expresses with HER2, a gene that has an increased presence in 20-30 percent of invasive human breast cancer and plays a major role in tamoxifen resistance. (uc.edu)
HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact? (medscape.com)
Two leading clinicians debated whether the differences between the three groups have clinical relevance or whether the degree of HER2 expression is merely a marker for other disease processes. (medscape.com)
Given currently available evidence, the case for whether HER2 low is or is not a clinical entity is finely balanced, he said. (medscape.com)

We conclude that ABCC3 is frequently amplified and overexpressed in HER2-positive breast cancer, and something that warrants further studies correlating the results with therapeutic outcome. (lu.se)

It is classified based on the overexpression of receptors on the cancer cell membrane. (aiche.org)

In this study, we assessed HER2/HER3. (koreamed.org)

No. UM500036) using human Her2 overexpression cell lysates and endogenous cell line lysates. (origene.com)
UM500036 can recognize the specific Her2 protein at predicted size (~140KDa) in overexpression cell ysate (lane 1 ) and endogenous lysates prepared from Hela, A549 and MCF7 cell lines. (origene.com)
UM500036 shows no cross-reactivity with other protein on the tested protein microarray containing >10,000 overexpression lysates for different human proteins. (origene.com)
UM500036 recognizes the specific Her2 protein at correct size in wild type Hela cell lysate (WT lane), and shows cross-reactivity with any other protein in the double knockout cell lysates (KO lane). (origene.com)

This finding could indicate that HER-2/neu expression is a new independent prognostic factor. (thieme-connect.de)

HER2 genes have instructions for making the HER2 protein. (medlineplus.gov)
Normally, you have two HER2 genes in each cell, one from each parent. (medlineplus.gov)
HER2 negative , which means your cancer cells have little to no HER2 protein or a normal number of HER2 genes. (medlineplus.gov)
There are different HER2 tumor marker tests for checking HER2 proteins and HER2 genes. (medlineplus.gov)

Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. (thieme-connect.de)
The global market for Her2 antibodies will be chiefly driven by the rising prevalence of breast cancer and an encouraging scenario of funding and regulatory support from cancer associations across the globe. (openpr.com)
Efforts directed towards this cause in the form of research and development will have a significant impact on the overall development of the global Her2 antibodies market in the next few years. (openpr.com)
From a geographical standpoint, the report covers the market for Her2 antibodies for regional markets such as North America, Europe, Asia Pacific, and Middle East and Africa. (openpr.com)
Of these, the North America market presently domiantes the global Her2 antibodies market owing to the high prevalence of breast cancer. (openpr.com)
Over the report's forecast period as well, North America will remain a lucrative regional market for Her2 antibodies, with factors such as the rapid pace of introduction of novel drug candidates and biosimilars boosting growth. (openpr.com)
Europe will also remain a key contributor of revenue to the global Her2 antibodies market, chiefly owing to favorable medical insurance policies and high disposable incomes of the population. (openpr.com)
The high demand for effective methods of treating breast cancer has opened vast growth opportunities for companies operating in the field of Her2 antibodies. (openpr.com)
The ever-expanding window of opportunity in the field has compelled many pharmaceutical companies to invest their funds and research efforts towards the development of effective drugs based on Her2 antibodies. (openpr.com)

Another study, presented at SABCS 2022, indicated that in a large nationwide US cohort, HER2 low status was associated with marginally improved survival in comparison with other groups. (medscape.com)

Around 3% of people with NSCLC have this kind of HER2 mutation. (cancer.gov)
characteristics, such as microsatellite instability-high (MSI-H), BRAF mutation , or HER2 overexpression. (jnccn.org)

Rates of HR + /HER2 - and triple-negative subtypes in AYAs varied substantially by race/ethnicity. (cdc.gov)

There is an approximate four-time greater risk of central nervous system disease in a HER2-positive population, Pegram explained, with brain metastasis appearing in approximately half of those who present with HER2-positive metastatic disease. (curetoday.com)
He warned, however, that no matter what the audience decided as a result of the debate, it should be borne in mind that the current HER2 assays were not designed to distinguish between HER2 low disease and disease in which there is no HER2 expression. (medscape.com)
With any other results, disease is currently classified as HER2 positive. (medscape.com)

Zhao J, Xia Y. Targeting HER2 alterations in non-small-cell lung cancer: a comprehensive review. (her2centrality.com)
Though no HER2-directed agents are approved in biliary tract cancer -- where HER2 is overexpressed up to 20% of the time -- several agents are recommended in guidelines, said Ko. (medpagetoday.com)
Overexpression is more frequently observed in extrahepatic cholangiocarcinomas and gallbladder cancer, for example. (medpagetoday.com)
Nelson, W.G. Retinoblastoma pathway dysregulation causes DNA methyltransferase 1 overexpression in cancer via MAD2-mediated inhibition of the anaphase-promoting complex. (hopkinsmedicine.org)
RÉSUMÉ Le cancer du sein est le type de malignité le plus courant en Iraq. (who.int)
Les résultats de cette étude justifient un renforcement des efforts visant à mettre en place des programmes complets de lutte contre le cancer du sein en Iraq. (who.int)
This type of cancer may grow more slowly than HER2-positive cancer. (medlineplus.gov)
This information shows how fast cancer may grow and whether medicine to target HER2 proteins may be helpful. (medlineplus.gov)
The cancer growing outside of your breast should be tested to see if it's HER2 positive, even if your breast tumor was already tested. (medlineplus.gov)
HER2 over-expression led to MED1 activation while reduction of MED1 caused breast cancer cells that were otherwise tamoxifen-resistant to respond and stop dividing. (uc.edu)
Genetic tests revealed that Romero had an overexpression of the HER2 gene, normally associated with breast cancer. (ucdavis.edu)
The American Cancer Society states that around 15-30% of breast cancer cases over-express the Her2 gene. (openpr.com)
He explained that it is not a clearcut question as to whether HER2 expression in breast cancer is either positive or negative, with the former implying some expression and the latter none at all. (medscape.com)
4 Approximately one in five cases of breast cancer are considered HER2 positive. (biospace.com)

HER2 overexpression down-regulated its expression. (nih.gov)
A key, and hitherto unanswered, question is, what is the level of HER2 expression needed for a response to treatment? (medscape.com)
10% HER2 expression is deemed negative as long as the result of immunohistochemical staining is weak and incomplete or the result of in situ hybridization (ISH) is negative. (medscape.com)
Four subgroups of breast carcinomas are distinguished Luminal A, Luminal B, HER2 over expression and Basal - like. (bvsalud.org)

Although, ErbB-2 does not have any known high-affinity ligands, its kinase activity can be activated without ligand by either overexpression or heteroassociation with other members of the ErbB family. (activemotif.com)

Proteomic data and in silico analyses revealed PI3K/Akt- and HER2-pathways among the predicted regulated pathways. (nih.gov)

Using today's immunohistochemistry tests to quantify low levels of HER2 "is like weighing mice on a scale built for elephants," Rimm said. (medscape.com)

Anatomy25

Organisms14

Diseases13

Chemicals and Drugs99

Analytical, Diagnostic and Therapeutic Techniques and Equipment36

Phenomena and Processes67

Disciplines and Occupations1

Information Science3

Amplification19

Tumors12

Cancers20

High levels of the HER2 protein1

Metastatic breast12

Protein overexpression2

ERBB27

Herceptin6

Patients22

Anti-HER2 antibody1

Trastuzumab9

Chemotherapy2

Antibody3

Colorectal cancer4

Epidermal growth8

Gastric2

Subtype1

Receptor8

Prognosis1

Estrogen1

Therapy4

Mutations4

Carcinoma1

Proliferation2

EGFR2

Therapeutic target2

Therapies3

Clinical7

Amplified and overexpressed1

Receptors1

HER31

Lysates4

Prognostic factor1

Genes4

Antibodies9

Survival1

Mutation2

Subtypes1

Disease3

Cancer14

Expression4

Kinase1

Pathways1

Immunohistochemistry1